Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

(2017) Lixia Gao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

(2017) Yong Teng et al.   Journal of Hematology & Oncology

The gentle art of saying NO: how nitric oxide gets things done in the hypothalamus

(2017) Konstantina Chachlaki et al.   Nature Reviews Endocrinology

Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90

(2017) Mariko Yoshida et al.   Scientific Reports

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

(2016) H. K. Sanoff et al.   ONCOLOGIST

Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

(2016) Masaki Kaibori et al.   Oncotarget

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice

(2015) Mei Zhou et al.   HEPATOLOGY

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

(2015) Chiara Degirolamo et al.   NATURE REVIEWS DRUG DISCOVERY

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

(2015) M. Hagel et al.   Cancer Discovery

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

(2014) M. Zhou et al.   CANCER RESEARCH

Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models

(2014) E. Ciamporcero et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma

(2014) B. Zhai et al.   MOLECULAR CANCER THERAPEUTICS

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

The yin and yang of nitric oxide in cancer progression

(2013) A. J. Burke et al.   CARCINOGENESIS

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis

(2012) Joanne Chiu et al.   CANCER

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth

(2012) Hannah van Malenstein et al.   CANCER LETTERS

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

(2012) A. Villanueva et al.   CLINICAL CANCER RESEARCH

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

(2011) Eric T. Sawey et al.   CANCER CELL

Mini-Review: Endocrine Actions of Fibroblast Growth Factor 19

(2008) Stacey Jones   MOLECULAR PHARMACEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE